Advertisement

Archives of Gynecology and Obstetrics

, Volume 294, Issue 6, pp 1133–1139 | Cite as

Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia

  • Franz Bahlmann
  • Ammar Al NaimiEmail author
Maternal-Fetal Medicine

Abstract

Purpose

The aim of this study is to assess the value of the angiogenic factors for diagnosing preeclampsia and predicting the severity of manifestation. A secondary aim is assessing the combination of the uterine artery Doppler with the angiogenic factors for improving the diagnostic power.

Methods

This is a prospective single center study in a tertiary referral hospital. This study includes 728 individual patients. Inclusion criteria were singleton pregnancies, a referral to the hospital with suspicion of preeclampsia and any one or combination of the following symptoms: headache, upper abdominal pain, edema, and hypertension. Patients with complications that would affect the course of the pregnancy, such as placenta praevia, premature preterm rupture of membranes, breech presentation, and fetal chromosomal or structural anomalies, were excluded from the study. Blood samples collection and uterine artery Doppler ultrasound were performed at time of recruitment. The differences in sFlt-1, PlGF, and their quotient among normal collective and patients with preeclampsia were analyzed. Doppler ultrasound was performed by one of four highly qualified sonographers. Wilcoxon–Mann–Whitney U test, Spearman’s rank correlation, receiver operating characteristic curves, Chi-square test, and logistic regression were used in the analysis.

Results

A total of 1003 individual samples for the angiogenic factors were included in the analysis. 584 out of the recruited 728 patients had follow-up data with delivery information at the study hospital. Patients with preeclampsia show a significant increase in sFlt-1, which directly correlate with the increased severity of manifestation (Spearman’s ρ 0.49). The sFlt-1 cut-off value of 5424 pg/ml confirms preeclampsia with 83.7 % sensitivity, 68.1 % specificity, and 24 % misclassification rate. Preeclampsia patients also show a significant decrease in PlGF, which negatively correlates with the increased severity of manifestation (Spearman’s ρ −0.39). A PlGF cut-off value of 118 pg/ml confirms preeclampsia with 47.6 % sensitivity, 71.4 % specificity, and 27 % misclassification rate. Logistic regression shows that a combination of the quotient from sFlt-1/PlGF with notching and uterine artery PI provides a valid model for diagnosing preeclampsia with a diagnostic power of 74.4 %.

Conclusions

The study confirms the use of the sFlt-1 and PlGF for diagnosing preeclampsia. It also shows their significance in differentiating between different categories of preeclampsia according to severity. This study shows that the use of angiogenic factors in combination with ultrasound findings provides valid models for confirming preeclampsia.

Keywords

Preeclampsia sFlt-1 PlGF Angiogenic factors Uterine artery Doppler 

Notes

Acknowledgments

This work was supported by the Dr. Senckenbergische Stiftung, Frankfurt am Main.

Compliance with ethical standards

Conflict of interest

Bahlmann and Al Naimi declare that we have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM (2001) The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20:IX–XIVCrossRefPubMedGoogle Scholar
  2. 2.
    Högberg U (2005) The World Health Report 2005: “make every mother and child count”—including Africans. Scand J Public Health 33:409–411CrossRefPubMedGoogle Scholar
  3. 3.
    Sibai B, Dekker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365:785–799CrossRefPubMedGoogle Scholar
  4. 4.
    Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A (1991) Placental beed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98:648–655CrossRefPubMedGoogle Scholar
  5. 5.
    Carbillon L, Challier JC, Alouini S, Uzan M, Uzan S (2001) Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta 22:795–799CrossRefPubMedGoogle Scholar
  6. 6.
    Talbert DG (1995) Uterine flow velocity waveform shape as an indicator of maternal and placental development failure mechanisms: a model-based synthesizing approach. Ultrasound Obstet Gynecol 6:261–271CrossRefPubMedGoogle Scholar
  7. 7.
    Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening Group (2001) Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 18:441–449CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160:1405–1423CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884–891CrossRefPubMedGoogle Scholar
  11. 11.
    Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRefPubMedGoogle Scholar
  12. 12.
    Krauss T, Pauer HU, Augustin HG (2004) Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 23:101–111CrossRefPubMedGoogle Scholar
  13. 13.
    Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA (2003) Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 188:177–182CrossRefPubMedGoogle Scholar
  14. 14.
    Bahlmann F, Fittschen M, Reinhard I, Wellek S, Steiner E (2012) Reference values for blood flow velocity in the uterine artery in normal pregnancies from 18 weeks to 42 weeks of gestation calculated by automatic Doppler waveform analysis. Ultraschall Med 33:258–264CrossRefPubMedGoogle Scholar
  15. 15.
  16. 16.
  17. 17.
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005CrossRefPubMedGoogle Scholar
  18. 18.
    Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936–943CrossRefPubMedGoogle Scholar
  19. 19.
    Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS (2001) Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 184:1267–1272CrossRefPubMedGoogle Scholar
  20. 20.
    Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ (1998) Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 179:1539–1544CrossRefPubMedGoogle Scholar
  21. 21.
    Mundim GJ, Paschoini MC, Araujo Júnior E, Da Silva Costa F, Rodrigues Júnior V (2016) Assessment of angiogenesis modulators in pregnant women with pre-eclampsia: a case-control study. Arch Gynecol Obstet 293:369–375CrossRefPubMedGoogle Scholar
  22. 22.
    Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM (2008) Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 111:1403–1409CrossRefPubMedGoogle Scholar
  23. 23.
    Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292:507–518CrossRefPubMedGoogle Scholar
  24. 24.
    Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202:161.e1–161.e11CrossRefGoogle Scholar
  25. 25.
    Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S (2016) Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374:13–22CrossRefPubMedGoogle Scholar
  26. 26.
    Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206:58.e1–8CrossRefPubMedGoogle Scholar
  27. 27.
    Fischer T, Schneider MP, Schobel HP, Heusser K, Langenfeld M, Schmieder RE (2000) Vascular reactivity in patients with preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 183:1489–1494CrossRefPubMedGoogle Scholar
  28. 28.
    Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H (2014) New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63:346–352CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyBuergerhospital, Dr. Senckenbergische StiftungFrankfurt Am MainGermany

Personalised recommendations